指南与共识泌尿男性生殖肿瘤

晚期前列腺癌最佳影像学策略:ASCO指南

Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2020-01-15

ASCO联合多家学会组成专家组,系统复习2013年至2018年8月文献,最终35项研究(17项系统评价和18项原始研究)构成证据基础,针对晚期前列腺癌不同临床场景提出影像学使用推荐,包括传统影像和下一代影像(NGI)如PET/CT、PET/MRI或全身MRI。

要点

  • 晚期前列腺癌患者应根据临床场景选用传统影像和/或下一代影像。
  • 传统影像定义为CT、骨扫描和/或前列腺MRI。
  • 下一代影像包括PET、PET/CT、PET/MRI或全身MRI。

核心结论

  • 对于晚期前列腺癌患者,应根据具体临床场景使用一种或多种影像学方法,包括传统影像和/或下一代影像。

研究设计与样本

  • ASCO联合腹部放射学会、美国放射学会、核医学与分子影像学会、美国泌尿外科学会、美国放射肿瘤学会和泌尿肿瘤学会组成专家组,系统复习2013年至2018年8月的英文文献,纳入35项研究(17项系统评价和18项原始研究)形成证据基础。

主要发现

  • 共35项研究符合纳入标准,包括17项系统评价(伴或不伴Meta分析)和18项原始研究文章。

关键数值与推荐

  • 推荐对晚期前列腺癌患者使用传统影像(定义为CT、骨扫描和/或前列腺MRI)和/或下一代影像(NGI,包括PET、PET/CT、PET/MRI或全身MRI),具体选择取决于临床场景。

临床怎么用

  • 临床医生应根据患者所处疾病状态(如疑似高危、初诊转移、局部治疗后疑似复发或系统治疗中进展)选择传统影像或下一代影像。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups. METHODS: An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment-naïve metastatic disease, suspected recurrent disease after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the literature from 2013 to August 2018 identified fully published English-language systematic reviews with or without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared ≥ 2 imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality. RESULTS: A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews with or without meta-analysis and 18 primary research articles. RECOMMENDATIONS: One or more of these imaging modalities should be used for patients with advanced prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Trabulsi EJ, Rumble RB, Jadvar H, et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020. PMID: 31940221. doi:10.1200/JCO.19.02757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。